GlobeNewsWire
13 Jun 2026, 01:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail announced that the NHS-Galleri Trial failed to observe a statistically significant reduction in Stage III-IV cancers, its primary endpoint. — Failure to meet a primary endpoint in a major clinical trial for a core product typically leads to massive valuation losses and loss of commercial viability.
-0.90Grail's stock price fell more than 50% following the announcement of the failed trial results on February 19, 2026. — A 50% price drop indicates a severe market repricing of the company's future cash flows and risk profile.
-0.70Robbins Geller Rudman & Dowd LLP has launched a class action lawsuit alleging Grail executives made false or misleading statements regarding the NHS-Galleri trial's probability of success. — Securities litigation introduces additional legal liabilities, management distraction, and potential future settlement costs.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a class action lawsuit following a 50% stock price drop due to failed primary endpoints in a clinical trial and allegations of misleading statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
3h ago
